Test your knowledge
Module 1: Patient identification and management
Introduction
People with chronic insomnia often experience more than just difficulties falling asleep, maintaining sleep and early morning awakening. They also have daytime consequences such as fatigue, attention deficits and mood instability.1,2 Although insomnia is the most common manifestation of sleep disorder, carrying a heavy burden for both patients and the healthcare system, it is often unrecognised and untreated due to barriers in its assessment and management.3
Learning objectives
By completing this module, you will increase your awareness and understanding of:
- the difference between acute and chronic insomnia
- tools available to aid diagnosis and when to refer
- available treatments and who QUVIVIQ™ is suitable for
Multiple-choice questions to test your current knowledge
Ready for the next step?
Diagnosing insomnia: acute vs chronic
ICD-11: International Classification of Diseases 11th Revision; NICE: National Institute for Health and Care Excellence.
QUVIVIQ™ is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.4
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to ds.safety.uk@idorsia.com
References
- World Health Organization (WHO). International statistical classification of diseases and related health problems (ICD) 11th revision. Available at: icd.who.int. Accessed August 2025
- Riemann D, Nissen C et al. The neurobiology, investigation, and treatment of chronic insomnia. Lancet Neurol 2015;14(5):547‑558
- Morin C M, Benca R. Chronic insomnia. Lancet 2012;379(9821):1129‑1141
- QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics
- Morin C M, Drake C L et al. Insomnia disorder. Nat Rev Dis Primers 2015;1:15026
© NICE 2023 Daridorexant for treating long-term insomnia. Available from www.nice.org.uk/guidance/ta922. All rights reserved. Subject to Notice of rights.
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/ publication.
UK-DA-00653 | Date of preparation: September 2025
